News on in vitro diagnostics for musculoskeletal disorders.
The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts.
The companies are applying Personalis' technology to explore immune response to genetic therapeutics in Sarepta's pipeline.
The alliance comes a few months after Shriners Hospitals established a new genomics institute in Tampa, Florida in partnership with Genome Medical.
Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
